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Crohn’s disease (CD) is a chronic progressive destructive disease.
Currently available instruments measure disease activity at a spe-
ciﬁc point in time. An instrument to measure cumulative struc-
tural damage to the bowel, which may predict long-term
disability, is needed. The aim of this article is to outline the meth-
ods to develop an instrument that can measure cumulative bowel
damage. The project is being conducted by the International Pro-
gram to develop New Indexes in Crohn’s disease (IPNIC) group.
This instrument, called the Crohn’s Disease Digestive Damage
Score (the Le ´mann score), should take into account damage loca-
tion, severity, extent, progression, and reversibility, as measured
by diagnostic imaging modalities and the history of surgical
resection. It should not be ‘‘diagnostic modality driven’’: for each
lesion and location, a modality appropriate for the anatomic site
(for example: computed tomography or magnetic resonance imag-
ing enterography, and colonoscopy) will be used. A total of 24
centers from 15 countries will be involved in a cross-sectional
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Inﬂamm Bowel Dis  Volume 17, Number 6, June 2011 1415study, which will include up to 240 patients with stratiﬁcation
according to disease location and duration. At least 120 additional
patients will be included in the study to validate the score. The
Le ´mann score is expected to be able to portray a patient’s disease
course on a double-axis graph, with time as the x-axis, bowel dam-
age severity as the y-axis, and the slope of the line connecting data
points as a measure of disease progression. This instrument could
be used to assess the effect of various medical therapies on the pro-
gression of bowel damage.
(Inﬂamm Bowel Dis 2011;17:1415–1422)
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resonance imaging
C
rohn’s disease (CD) is a chronic inﬂammatory bowel
disorder which usually follows a relapsing and remit-
ting course (ﬂare-ups followed by clinical remission) in the
early phases of the disease. Relapses are characterized by
clinical symptoms associated with biological, endoscopic,
and histological signs of inﬂammation. Even during periods
of clinical remission, the bowel is not free of lesions; sub-
clinical inﬂammation often persists and there is an evolu-
tion to ﬁbrostenotic stricture or penetrating lesions (ﬁstula
and abscess) of the bowel, reﬂecting a progressive, destruc-
tive disease course in the later phases of the disease, result-
ing in structural bowel damage. Surgical resection of bowel
is frequently required to treat strictures, ﬁstula, or abscess,
and it should be recognized that surgically resected bowel
is the ultimate manifestation of bowel damage.
1 Following
surgery, this cycle often recurs, leading to progressive loss
of intestinal function and disability.
Until now, the structural bowel damage component of
CD has not been examined, with the therapeutic focus being
on the assessment of disease activity judged by the severity
of symptoms and inﬂammation. To assess the severity of
clinical disease activity, composite scores such as the
Crohn’s Disease Activity Index (CDAI) or the Harvey–Brad-
shaw Index are used. To assess the severity of endoscopic
inﬂammation, the Crohn’s Disease Endoscopic Index of Se-
verity (CDEIS), the Simpliﬁed Endoscopy Score (SES-CD),
or, in the postoperative setting, the Rutgeerts’ score were
developed for use in clinical trials.
2–8 These instruments esti-
mate the severity of disease activity or inﬂammation and are
currently the standard by which the efﬁcacy of new products
is assessed in clinical trials. While they can assess the sever-
ity of inﬂammatory activity at a speciﬁc timepoint, they do
not gauge the cumulative structural bowel damage and thus
do not capture the progressive, destructive course of the dis-
ease. For instance, CDAI and CDEIS scores can be similar
in both patients with recent onset CD who are naı ¨ve to treat-
ment and in patients with a long history of CD who have
extensive, irreversible bowel damage from progressive
inﬂammation or previous surgical resection.
The characterization of CD as a progressive, destruc-
tive disease is not new, but has become better recognized
through longitudinal follow-up studies of large cohorts of
patients with CD. Before these studies, CD was often
regarded as a heterogeneous entity with different pheno-
types. In 1998 the Vienna classiﬁcation identiﬁed three
subgroups of patients according to disease behavior: B1,
purely inﬂammatory (nonpenetrating, nonstricturing); B2,
ﬁbrostenotic; and B3, penetrating.
9 On this schematic clas-
siﬁcation, patients were assumed to show different patterns
of evolution. In 2002, Louis et al
10 and Cosnes et al
11 inde-
pendently demonstrated that most patients with CD actually
had a nonpenetrating nonstricturing phenotype at diagnosis,
but progressed to stricturing and penetrating lesions over
the long term. They demonstrated that the natural history
of CD is a dynamic process, leading to irreversible bowel
damage in the large majority of patients. The ﬁndings of
these referral center studies have recently been conﬁrmed
in a population-based cohort.
12
The view of potential treatment goals in CD has also
changed.
13 The therapeutic objective is now evolving: it is
not only to control disease activity in terms of clinical
symptoms and inﬂammatory markers, but also to prevent
progression of structural bowel damage. As in rheumatoid
arthritis and other destructive inﬂammatory conditions,
early intervention is being considered to prevent irreversi-
ble damage.
14 A novel randomized trial compared two
strategies, early combination immunosuppressive and anti-
tumor necrosis factor (TNF) biologic treatment (top-down)
versus a conventional step-up approach in patients recently
diagnosed with CD.
15 Although early intensive treatment
accelerated clinical remission and limited corticosteroid ex-
posure during the ﬁrst year, the rate of clinical remission
without steroids was similar for both strategies during the
second year. These results can be interpreted in two con-
trasting ways: 1) early intervention was not more effective
than the conservative strategy in preventing disease pro-
gression; 2) early intervention was effective, but the end-
points to assess disease progression were not appropriate.
This result strongly suggests that long-term endpoints
including assessment of bowel damage might demonstrate
a beneﬁt with early intensive treatment.
The concept of tissue damage has been explored
extensively in rheumatoid arthritis. A speciﬁc damage
index score measuring joint erosion and destruction over
time using radiographs has been developed and is used to
measure disease progression.
16–19 Surface erosion and
joint-space narrowing were selected as the most relevant
criteria, because they occur frequently and are independent
of each other. These two types of lesions are assessed on
standard x-rays of hands, wrists, and feet. According to the
severity of lesions in 28 joints graded on a semiquantitative
scale, a score ranging from 0 to 448 is derived. Repeat X-
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1416ray can be used to assess the progression of joint damage.
19
Since its development and validation, the modiﬁed Sharp
index has been used in numerous clinical trials to compare
various treatments and treatment strategies in patients with
rheumatoid arthritis.
20–24
The ﬁrst bowel damage score for CD, proposed by
Cosnes et al,
25 was primarily a weighted cumulative mea-
surement of surgically resected bowel. More recently,
novel imaging methods, including abdominal endosonogra-
phy, computed tomography enterography (CTE), and mag-
netic resonance imaging enterography (MRE), have pro-
vided accurate methods to identify structural bowel
damage.
26–41 These tools can therefore be used to develop
an instrument analogous to the modiﬁed Sharp index to
quantify damage, whether surgically resected bowel or
bowel that remains in vivo. Such an instrument could mea-
sure disease progression over time and assess the impact of
treatment strategies on the progression of CD.
The objective of this article is to describe the methods
that will be used to develop this new instrument: the Crohn’s
Disease Digestive Damage Score (The Le ´mann score).
METHODOLOGY OF THE DEVELOPMENT
OF THE LE ´MANN SCORE
The International Program to develop New Indexes
in Crohn’s disease (IPNIC) group was formed in 2007.
42 It
is an international working group under the auspices of the
French association INTESTINFO. It comprises 28 gastro-
enterologists from 15 countries, one surgeon, two radiolog-
ists, and one biostatistician. One of its objectives is to de-
velop an instrument that can measure the cumulative bowel
damage in patients with CD, the Le ´mann score.
Expected Characteristics of the Le ´mann score
IPNIC group members have recommended that the
Le ´mann score should be able to: 1) measure cumulative
bowel damage at a speciﬁc time in a patient’s history; 2)
measure the progression of bowel damage over time in
cohorts of patients and in clinical trials; 3) identify patients
with CD at high (or low) risk of rapid damage progression;
and 4) compare the effects of treatment on the progression
of bowel damage to determine the responsiveness of the
index.
The score should measure cumulative digestive tissue
damage and be based on a comprehensive assessment of
structural bowel damage, including stricturing lesions, pen-
etrating lesions (ﬁstulas and abscesses), and surgical resec-
tion. Its applicability should be broad and it should allow
all patients to be assessed at different clinical stages (early
or advanced CD, operated or nonoperated, with limited or
extensive CD).
The assessment methods should be ‘‘damage driven’’
(i.e., based on damage location, extent, and severity, using
appropriate diagnostic imaging modalities or a history of
surgical resection) and not be ‘‘diagnostic modality
driven.’’ The optimal diagnostic modalities may change
with time and technical progress, but should be determined
by the type of lesion and location (for example, CTE or
MRE, and colonoscopy).
The index score should take into account damage
location, extent, and severity. Damage location (upper di-
gestive tract, small bowel, colon or rectum, and anal or
perianal) is necessary to take into account the relative clini-
cal importance of the location of the damage for progres-
sion (such as upper gastrointestinal disease) or outcome
(such as perianal disease). To evaluate damage extent, the
digestive tract will be divided into segments based on their
clinical relevance, frequency of involvement, feasibility of
deﬁning limits to one given segment, and the Montreal
Classiﬁcation of disease.
43 For each segment, severity will
be scored on an ordinal scale ranging from 0 (normal) to 3
(maximal) for stricturing lesions, penetrating lesions, and
surgical resection or bypass of bowel. As an example, Ta-
ble 1 shows the severity grades proposed for small bowel
TABLE 1. Severity Scale for Small Bowel Lesions According to the Lesions or History of Surgery or Any Other
Interventional Procedure
Grade Stricturing Lesions Penetrating Lesions
History of Surgery or Any
Other Interventional Procedure
0 Normal Normal None
1 Wall thickening <3 mm and/or
segmental enhancement without
prestenotic dilatation
——
2 Wall thickening 3 mm and/or mural
stratiﬁcation without prestenotic
dilatation
Deep transmural
ulceration
Bypass diversion or
stricturoplasty
3 Stricture with prestenotic dilatation Abscess or any type of
ﬁstula
Resection
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ventional procedures. Weighting coefﬁcients for individual
items can be determined statistically or by expert
consensus.
Finally, the score should vary from zero (no digestive
damage) to a theoretical maximum value corresponding to
complete resection of the digestive tract.
Digestive Damage Assessment Methods
CTE and MRE have greatly improved the detection of
structural small bowel lesions in CD.
26–41 The high quality
of images has made it possible to visualize precisely the
location of lesions, bowel wall involvement, fat or mesen-
teric changes around segments of the gastrointestinal tract,
and the presence of strictures, ﬁstulas, or abscesses. A pre-
cise cartography of CD lesions is now possible.
Ultrasound
Ultrasound can be an informative imaging modality
when performed by an experienced operator under ideal
conditions. It provides an excellent view of the intestinal
wall and can detect the presence of complications, particu-
larly in ileal CD. In several studies its accuracy was com-
parable to that of MRE for evaluating wall thickening and
disease activity.
44 However, the use of ultrasound, particu-
larly in clinical trials, is limited by the fact that it is highly
operator-dependent, difﬁcult to standardize examinations
between centers, and difﬁcult to acquire images that can be
archived for serial comparisons over time. Central reading
of ultrasound images is also challenging,
34 because infor-
mation is gained in real time. The ability of ultrasound to
quantify the anatomic disease extent, particularly in small
bowel CD, is therefore limited.
Computed Tomography Enterography
CTE has demonstrated over 80% sensitivity and spec-
iﬁcity for detecting bowel segments affected by CD, as it
allows multiplanar reformation with isovoxel resolu-
tion.
44,45 In addition, CTE can easily be standardized, and
images can be read centrally. The main drawback of CTE
is the risk of repeated radiation exposure associated with
the need for follow-up studies; recent publications have
emphasized the potential risk of gastrointestinal cancer
associated with repetitive use of abdominal computed to-
mography, especially in patients exposed at a young age.
45
Even though this risk is low and theoretical, being based
on extrapolations from the observed risk at higher exposure
levels, it must be considered in CD, because the affected
patient population is young and will require frequent
reassessment.
Magnetic Resonance Imaging Enterography
MRE protocols used to assess bowel lesions in CD
are similar to those used for CTE.
35–38 MRE combines
high-tissue-contrast examination with multiplanar acquisi-
tions of the abdomen.
46 Detection rates in publications
with the latest generation of magnetic resonance imaging
(MRI) equipment are generally similar to those achieved
by CTE. A recent study underlined the accuracy of MRI
for measuring disease activity in ileocolonic CD, with
results comparable to colonoscopy.
39 Nonetheless, access
to MRI remains limited in some countries; image acquisi-
tion and analysis still takes longer than for CTE; and the
value of colonic MRI needs to be validated by other cen-
ters. MRE has the potential to be the most useful imaging
modality to evaluate bowel damage because of its accu-
racy, lack of ionizing radiation, and ability to detect pene-
trating complications of CD.
Upper Endoscopy and Colonoscopy
Upper gastrointestinal endoscopy and colonoscopy
can identify mucosal lesions that more accurately reﬂect
disease activity (inﬂammation) than bowel damage. The
low frequency of the involvement of the upper tract in CD
(<15%) is unlikely to justify routine upper endoscopy for
the purposes of the present instrument.
47 Colonoscopy, on
the other hand, has been recommended for assessment of
colonic damage because, despite improvements in MRI
technique, biopsy conﬁrmation of the nature of lesions and
potential therapy can be performed with one technique.
The inability of endoscopy or colonoscopy to evaluate
lesions outside the bowel, as well as the interventional na-
ture of examination often performed under sedation, are
limitations of the techniques.
Cross-sectional Study Aimed at
Developing the Le ´mann score
The main objective of this multicenter, cross-sec-
tional study is to develop an instrument that can measure
the cumulative bowel damage at a speciﬁc point in time.
Study Design
Twenty-four centers in 15 countries will be involved in
the collection of data. Each center will include at least one
set of 10 patients (learning test set), and some centers will
include an additional set of 10 patients (validation set). The
Le ´mann score should allow patients to be assessed at differ-
ent clinical stages (early or advanced CD, operated or nonop-
erated) and with four disease locations (upper gastrointestinal
tract, small bowel, colon and/or rectum, and anal locations).
Therefore, patients will be stratiﬁed within each center
according to their present CD location and disease duration
(<2 years, 2–10 years and 10 years) except for the upper
gastrointestinal location, which is less frequent than the other
CD locations. A target number of patients will be recruited
into each stratum (Table 2).
The ﬁnal population will include up to 240 patients
for the descriptive (learning test) set and a minimum of
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tion set will be pooled with the descriptive (learning) set
and bootstrap methods used to generate samples to evaluate
the quality of the damage severity score, per disease loca-
tion and globally.
To be included, patients should have abdominal MRE
and pelvic MRI, upper endoscopy, and colonoscopy,
according to their CD location (Table 3). If patients have
abdominopelvic CTE, data will also be analyzed. MRI and
CT data (if available) will be read by both the investigator
and the investigative site radiologist.
Finally, for each CD location and globally for the
whole gut the investigator will make an overall evaluation
of damage severity on a visual analog scale (VAS) ranging
from 0 (no damage) to 10 (complete destruction).
Data Analysis
Le ´mann score construction. The principle of the construc-
tion process will be to derive a score that is strongly corre-
lated with the dependent variables: i.e., overall damage se-
verity at each location and global damage severity for the
whole digestive tract. This score will be based on independ-
ent ordinal variables describing lesions (strictures, penetration
by ulcers, ﬁstulas and abscess, and surgical resection of
bowel) in each segment for the four CD locations. Bowel
damage scoring will therefore be conducted in several steps.
In the ﬁrst step, each location will be studied sepa-
rately. For each CD location, independent variables will be
coded as follows: (a) presence of a segment with at least
grade 1, 2, or 3 lesion/surgery; (b) number of segments with
at least grade 1, 2, or 3 lesion/surgery; (c) the proportion of
segments containing grade 1, 2, or 3 lesion/surgery will also
be assessed (if feasible) in the case of small bowel location;
(d) only the presence of variables will be used in the case of
anal location. The dependent variable will be the overall
damage severity in the location as evaluated on a linear
VAS. Multiple linear regression with both forward and back-
ward selection procedures using the likelihood ratio test will
be used to derive a location damage severity score as a lin-
ear combination of independent variables, describing pres-
ence and numbers or percentages of segments containing
one type of lesion/surgery; this will be a combination that is
strongly correlated with the dependent variable (overall
damage severity in the CD location). For each CD location
the score will be simpliﬁed as much as possible by rounding
and grouping coefﬁcients in the linear combination.
The second step is the analysis of data from all loca-
tions together. The aim of this second step is to test
whether a common linear combination of independent vari-
ables could be applied to the different locations to predict
the dependent variables. This procedure will use a mixed
multiple linear model.
The third step will be to determine the weightings to
be applied to each evaluation of overall damage severity in
the various locations in calculating the global damage se-
verity score. This will be performed by linear multiple
regression, with the global evaluation as dependent variable
and the four overall location damage severity evaluations
as independent variables. The applicability of the model
will be carefully checked. If the results of the third step are
TABLE 2. Patients Enrolled Into Each Set (Learning Test
or Validation) in Each Center
Patient No. CD Location
a CD Duration
1 Upper digestive tract —
b
2 Small bowel < 2 years
3 Small bowel [2-10] years
4 Small bowel  10 years
5 Colon and/or rectum < 2 years
6 Colon and/or rectum [2-10] years
7 Colon and/or rectum  10 years
8 Perianal and anal < 2 years
9 Perianal and anal [2-10] years
10 Perianal and anal  10 years
aPatient will have to present with at least the following CD location.
bRegardless of disease duration.
TABLE 3. Examinations
a Required for Inclusion in the Study Aimed to Develop the Le ´mann score, According to
Crohn’s Disease Location
CD Location UpperEndoscopy Colonoscopy
Abdominal MRI
Enterography PelvicMRI
Abdominopelvic
CT Enterography
b
Upper digestive tract X X X
Small bowel X X
Colon and/or rectum X X X
Perianal and anal X X X
CD, Crohn’s disease; CT, computed tomography; MRI, magnetic resonance imaging.
aAdditional examinations may be performed at the discretion of the investigator but are not required for inclusion in the study.
bCT enterography will be performed only in some patients.
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by consensus. If the results obtained on the ﬁrst and/or
third steps seem encouraging, but could be improved by
increasing sample size, the learning and validation test sets
will be pooled to construct the index.
Le ´mann score validation. Results obtained in the ﬁrst
step, possibly simpliﬁed in the second step, will be validated
by calculating the damage severity score within each location
from data in the validation set. Parametric and nonparametric
correlation coefﬁcients between the calculated damage sever-
ity score and the damage severity assessment will be esti-
mated, both by location and globally. If necessary, bootstrap
methods will be used to generate new samples.
Complementary studies. The reproducibility of the MRI
examination will be analyzed from the MRI recordings,
with additional information from other sources (history of
surgery, and results of complementary examinations such
as colonoscopy, or clinical anal examination). Concordance
between MRI and CT detection of strictures and penetrat-
ing lesions (ﬁstulas and abscesses) will also be studied on
a sample of patients with both MRI and CT data.
DISCUSSION
The concept of CD as a progressive disease inducing
cumulative structural damage has emerged over recent
years.
10–12 The present article describes the methodology
for developing an instrument, called the Le ´mann score,
which should enable assessment of cumulative structural
bowel damage at a given time in a CD patient’s history,
taking into account both the extent and severity of bowel
damage, including stricturing and penetrating lesions and
previous surgery. Damage will be assessed based on the
medical history, endoscopy, and other imaging techniques.
It also offers the potential for evaluating the rate and pro-
gression of damage over a period of time through serial
assessment. This should allow the effect of therapeutic
intervention to be assessed.
For each lesion and location, the current optimal
diagnostic imaging modality will be used. Imaging modal-
ities are likely to evolve through technical progress. Of
particular importance is that the number of tools used to
construct the index should be as small as possible, to facili-
tate widespread use of the index. Ideally, a single investi-
gation should be selected, MRE being a good candidate.
However, access to abdominal and pelvic MRI is still lim-
ited, as may be radiological expertise, while the accuracy
of MRE for assessment of the colon is still being eval-
uated. For the development of the Le ´mann score we have
decided to include patients with additional investigations
according to disease location in order to explore the infor-
mation they could provide. More speciﬁcally, the useful-
ness of endoscopy has been debated: IPNIC group mem-
bers decided that at this stage in the development of the
score, colonoscopy is necessary for patients with a history
of colonic involvement, to detect colonic strictures, and
upper endoscopy for those known to have upper digestive
tract disease. Pelvic MRI was also regarded as necessary in
all patients with a history of perianal disease, whatever the
results of clinical examination. It is also planned to include
patients having both CT and MRI, to determine whether
diagnostic modality may be used interchangeably.
We expect that the Le ´mann score for a patient will
be graphically represented on a double-axis graph, with
time as the x-axis and bowel damage severity as the y-axis
(Fig. 1). The location of the patient on the graph will
describe cumulative disease damage at a speciﬁc point in
time in the patient’s history. At present, this information is
intuitively taken into account by clinicians in therapeutic
decision-making, but is not formally quantiﬁed. Damage
severity is not taken into account in clinical trials or cohort
studies for selection of patients or assessment of drug efﬁ-
cacy. The Montreal Classiﬁcation provides a crude picture
of damage, with location (L) and behavior (B) of the dis-
ease. For instance, a patient with limited ileal disease expe-
riencing obstructive symptoms will be in the same category
(L1, B2) as one with extensive small bowel disease, multi-
ple strictures, and previous intestinal resection; obviously,
therapeutic decisions may be different between these two
patients. The Le ´mann score should provide a better mea-
surement of the severity of structural bowel damage and
may be used to measure bowel damage progression with
repeated assessments. The slope of the curve of digestive
damage could be taken into account for decision-making,
independently of damage severity. As in rheumatoid
FIGURE 1. Progression of digestive damage and inﬂamma-
tory activity in a theoretical patient with CD.
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1420arthritis, the slope of the curve may allow patients with
rapid damage progression to be selected in order to propose
intensiﬁed therapy, or to use in other cases less aggressive
treatment. The effects of medical therapies or strategies on
disease progression could also be evaluated.
The present article introduces the basis for the devel-
opment of the CD digestive damage score, the Le ´mann
score. Such a score should allow better identiﬁcation of
patients with severe damage and those with rapid progres-
sion of damage. The Le ´mann score has the potential to be
integrated into clinical trials or prospective evaluation of
cohorts of patients in the near future. In particular, justiﬁ-
cation for early intervention with immunosuppressive and/
or biologic agents could be strengthened if an impact can
be demonstrated on digestive disease damage.
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